Amiodarone-induced pulmonary toxicity can rarely occur even after a short course of therapy, highlighting the need for clinical vigilance.
Answers are grounded in this paper and cite their sources.
Short-course amiodarone may still cause pulmonary toxicity; this case report leaves open incidence, risk factors, and monitoring needs.
Amiodarone is one of the most commonly prescribed antiarrhythmic drug for almost all atrial or ventricular arrythmias. Amiodarone-induced pulmonary toxicity (APT) was first described in 1980 and has potentially serious side effects that are believed to develop in 5% of patients. In general, APT occurs only when high amiodarone doses are used for a long time. However, during short-term therapy of amiodarone, APT is rarely reported. In this report, we describe a case of amiodarone-induced pulmonary toxicity after a short course of amiodarone therapy for atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: